ARTICLE | Company News
Targeted Genetics other research news
October 14, 1996 7:00 AM UTC
TGEN received a $700,000 Phase II SBIR from the National Institute of Diabetes, Digestive and Kidney Diseases to develop large-scale methods to produce AAV-CFTR vectors to support trials in CF patient...